How much pharmacological therapy can be incorporated into arteriovenous malformation management?

Pharmacological therapy for arteriovenous malformations (AVMs) remains experimental. There have been quite a lot of efforts to identify a drug or molecules with selective activity for AVM as angiogenic inhibitors (e.g., octreotide, rapamycin). However, identification of an effective drug is still pending.